FIGURE 1 Effect of the analogue of firsocostat (ACCi) and fenofibrate (Feno) as monotherapies or in combination in fast‐food diet (FFD)–fed mice. Terminal body weight (A), liver triglycerides (TG) (B), plasma β‐hydroxybutyrate (BHB) (C), liver BHB (D), plasma acylcarnitine (E), liver acylcarnitine (F), and circulating TG (G) collected in the fed state, 2 h following dose, after 15 days of dosing. (H) Plasma ApoC3 collected after a short fast after 14 days of dosing. (I) Terminal hepatic lipid peroxidation assessed by malondialdehyde content. (J) Quantitation of hepatic F4/80 +  immunostaining. (K) Hepatic collagen type I alpha 1 chain ( Col1a1 ) expression. (L,M) Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. Unless otherwise specified, data are presented as mean ± SEM ( n  = 10–15 animals/group). In (E) and (F), data are presented as log 2 (fold change relative to chow), and in (K) data are presented as fold change relative to chow. * p  ≤ 0.05, ** p  ≤ 0.01, *** p  ≤ 0.001, **** p  ≤ 0.0001 versus vehicle;  † 
 p  ≤ 0.05,  †† 
 p  ≤ 0.01,  ††† 
 p  ≤ 0.001,  †††† 
 p  ≤ 0.0001 versus ACCi monotherapy, or as indicated;  ‡ 
 p  ≤ 0.05,  ‡‡ 
 p  ≤ 0.01,  ‡‡‡ 
 p  ≤ 0.001,  ‡‡‡‡ 
 p  ≤ 0.0001 versus Feno low  or Feno high  monotherapy.